Diagnostics News and Research RSS Feed - Diagnostics News and Research

Luminex provides clinical trial update on ARIES HSV 1&2 Assay

Luminex provides clinical trial update on ARIES HSV 1&2 Assay

Luminex Corporation today announced that testing at the clinical trial sites for the ARIES HSV 1&2 Assay is now complete. The next steps, including site to site reproducibility testing, followed by data analysis and assembly of the data package for submission to the FDA, are now underway. [More]
PAML signs collaborative agreement with Axela

PAML signs collaborative agreement with Axela

PAML announced today that the laboratory has entered into a collaborative agreement with Axela, Inc. to develop multiplex assays focused on immune status for vaccine preventable diseases. PAML is one of the nation's leading medical reference laboratories, and Axela focuses on multiplexed nucleic acid and protein analysis for clinical diagnostics. [More]
PCDx test performs better than FoundationOne test in clinical study

PCDx test performs better than FoundationOne test in clinical study

Data from a small cohort published OncoTargets and Therapy today shows that the Paradigm Cancer Diagnostic Test (PCDx) performed better than Foundation Medicine's FoundationOne test across a number of key clinical variables, including turnaround time (TAT) and clinically actionable biomarker targets. [More]
Vermillion reports expanded medical policy coverage of OVA1 test

Vermillion reports expanded medical policy coverage of OVA1 test

Vermillion, Inc., a bio-analytical solutions company focused on gynecologic disease, today announced expanded medical policy coverage of its OVA1 test, following Blue Cross Blue Shield of Michigan's recent decision to include OVA1 in its medical policy guidelines. [More]
Check-Cap announces Notice of Allowance from USPTO for endoscopy capsule technology

Check-Cap announces Notice of Allowance from USPTO for endoscopy capsule technology

Check-Cap Ltd., a clinical stage medical diagnostics company engaged in the development of a preparation-free ingestible imaging capsule that utilizes low-dose X-rays for the screening for colorectal cancer, today announced receipt of a Notice of Allowance from the United States Patent and Trademark Office for patent application U.S. 13/825,018 entitled, "Estimation of Distances and Size of Lesions in the Colon with an Imaging Capsule." [More]
Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer

Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer

Merrimack Pharmaceuticals, Inc. and Baxter International Inc. today jointly announced that Merrimack has completed the rolling submission of the New Drug Application (NDA) for MM-398 (irinotecan liposome injection), also known as "nal-IRI," to the U.S. Food and Drug Administration. [More]
Haemonetics' revenue for fourth quarter fiscal 2015 down 6%

Haemonetics' revenue for fourth quarter fiscal 2015 down 6%

Haemonetics Corporation today reported revenue for the fourth quarter fiscal 2015 of $226.5 million, down 6%. Excluding currency impact, revenue was down 4% in the quarter. The Company reported a fourth quarter GAAP net loss of $2.9 million or $0.06 per share. [More]
Ikonopedia's breast imaging reporting tools, MQSA management system selected for use by BelleBridge

Ikonopedia's breast imaging reporting tools, MQSA management system selected for use by BelleBridge

Ikonopedia announced today that its breast imaging reporting tools and MQSA management system have been selected for use by BelleBridge, which provides telemedicine services for interpretations of breast screening and diagnostic examinations. [More]
Debiopharm announces initiation of Debio 1450 phase II study for treatment of ABSSSI

Debiopharm announces initiation of Debio 1450 phase II study for treatment of ABSSSI

Debiopharm International SA, part of Debiopharm Group, a Swiss-based global biopharmaceutical company, today announced the start of a clinical phase II study to evaluate Debio 1450 for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) due to Staphylococci, including all resistant Staphylococcus strains, tested so far. [More]

Quest Diagnostics' revenues grow 5.3% to $1.84 billion in first quarter 2015

Quest Diagnostics Incorporated, the world's leading provider of diagnostic information services, announced today that for the first quarter ended March 31, 2015, adjusted net income was $141 million, compared to $122 million in 2014. Adjusted diluted EPS excluding amortization was $1.05 in the quarter, compared to $0.93 in 2014. Amortization expense was $0.09 per diluted share in both years. [More]
AMP report provides overview of current research on minimally invasive 'liquid biopsy' approaches

AMP report provides overview of current research on minimally invasive 'liquid biopsy' approaches

The Association for Molecular Pathology, the premier global, non-profit organization serving molecular diagnostic professionals, today published a special article in The Journal of Molecular Diagnostics titled, "Do Circulating Tumor Cells, Exosomes, and Circulating Tumor Nucleic Acids Have Clinical Utility?" The report provides a thorough overview of research to-date on the minimally invasive "liquid biopsy" approaches to cancer diagnostics. [More]
EKF launches next generation Hemo Control POC hemoglobin analyzer

EKF launches next generation Hemo Control POC hemoglobin analyzer

Available as a cost effective basic device which stores up to 4000 patient results, the new Hemo Control offers enhanced on-board Data Management (DM) functions following upgrade with the DM ‘add pack’ if required at a later date... [More]
Sysmex Inostics to offer OncoBEAM CLIA laboratory services in Germany, Austria and Switzerland

Sysmex Inostics to offer OncoBEAM CLIA laboratory services in Germany, Austria and Switzerland

Sysmex Inostics, a subsidiary of Sysmex Corporation, today announced that they have signed an exclusive distributor agreement with IndivuTest GmbH, and its parent company Indivumed GmbH, a cancer research company focused on the development of individualized cancer diagnostics and therapies. [More]

Unique approach to academia-industry training could help improve proton therapy treatment

Improving proton therapy for cancer treatment is one of the many advances in accelerator science that have been fast-tracked by a unique approach to academia-industry training, led by the Cockcroft Institute. The two programmes, which have produced 42 highly valued research fellows, are drawing to a conclusion and industry partners are warning of a skills chasm in the very near future unless further training is prioritised. [More]
Novel approach allows real-time imaging of ongoing immune response

Novel approach allows real-time imaging of ongoing immune response

A novel approach that allows real-time imaging of the immune system's response to the presence of tumors—without the need for blood draws or invasive biopsies—offers a potential breakthrough both in diagnostics and in the ability to monitor efficacy of cancer therapies. [More]
New clinical utility data for Guardant360 platform to be presented at 2015 AACR Annual Meeting

New clinical utility data for Guardant360 platform to be presented at 2015 AACR Annual Meeting

Guardant Health today announced new clinical utility data for its Guardant360 platform, which will be presented at the 2015 American Association for Cancer Research (AACR) Annual Meeting in Philadelphia. [More]
Paradigm to provide PCDx test to oncologists in TD2 networks

Paradigm to provide PCDx test to oncologists in TD2 networks

Paradigm and Translational Drug Development today announced a partnership under which Paradigm will provide their PCDx test to TD2's affiliated oncology provider networks. [More]
Contego Medical announces completion of $5.6 million Series B financing round

Contego Medical announces completion of $5.6 million Series B financing round

Contego Medical, the first and only provider of the Integrated Embolic Protection filter platform for angioplasty balloon and stent delivery catheters, announces the completion of a $5.6 million Series B financing round led by Hatteras Venture Partners, an early stage venture firm with a focus on medical devices, biopharmaceuticals, diagnostics and related opportunities in human medicine. [More]
Cepheid, FIND announce receipt of CE-IVD status for Xpert HIV-1 Qual test

Cepheid, FIND announce receipt of CE-IVD status for Xpert HIV-1 Qual test

Cepheid and FIND today announced that Xpert HIV-1 Qual, a qualitative 90-minute molecular HIV test, has achieved CE-IVD status under the European Directive on In Vitro Diagnostic Medical Devices. [More]

Leica Biosystems announces launch of Aperio VERSA scanner at AACR annual meeting

Leica Biosystems announces the introduction of the Aperio VERSA, a combination digital pathology research scanner for brightfield, fluorescence and FISH imaging at the American Association for Cancer Research annual meeting in Philadelphia, opening on April 18th, 2015. [More]
Advertisement
Advertisement